Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) will host a conference call on November 8, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. Investors can join by dialing (844) 388-0559 in the U.S. or (216) 562-0393 internationally, using conference ID 6187211. A live audio webcast will be available on Avadel's investor relations website, with a replay accessible for 90 days. The company focuses on developing innovative medications, notably its lead candidate FT218 for narcolepsy.

Positive

• The conference call will provide insights into financial performance.
• Focus on innovative drug development with FT218 targeting narcolepsy.

Negative

• None.

DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 6187211. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

When will Avadel Pharmaceuticals discuss its third-quarter financial results?

Avadel Pharmaceuticals will discuss its third-quarter financial results on November 8, 2021, during a conference call at 8:30 a.m. ET.

How can I access the Avadel Pharmaceuticals conference call?

Investors can access the conference call by dialing (844) 388-0559 in the U.S. or (216) 562-0393 internationally, with conference ID 6187211.

What is FT218 and how does it relate to Avadel Pharmaceuticals?

FT218 is an investigational formulation of sodium oxybate being developed by Avadel Pharmaceuticals for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

Is there a replay available for the Avadel Pharmaceuticals conference call?

Yes, a replay of the conference call will be archived on Avadel's website for 90 days following the event.